Trending:
Comment
-
15 June 2018
Lanabecestat termination: another blow for BACE inhibitors
After the disappointing failures of highly anticipated anti-amyloid pipeline drugs, such as Pfizer/Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab, the focus of research in Alzheimer’s has increasingly turned to...
-
15 June 2018
EULAR 2018: Focus on infliximab biosimilars in rheumatoid arthritis
On June 14th, Biocad presented Week 14 results on the safety and efficacy of BCD-055 (infliximab biosimilar) from the ongoing Phase III LIRA clinical trial. The international, multicenter, double-blind, placebo-controlled...
-
15 June 2018
Pfizer’s blockbuster drug Lyrica comes off-patent in 2018
Lyrica, Pfizer’s blockbuster anticonvulsive treatment, is expected to come off-patent in December 2018, leading to a dramatic reduction in sales due to generic erosion.
-
13 June 2018
Northwest Bio’s DCVax-L: is the hype warranted for glioblastoma patients?
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer; little progress has been made toward its treatment in the past decade. However, on May 29 Northwest Bio revealed...
-
13 June 2018
ASCO data sees Merck’s Keytruda pull ahead of Roche’s Tecentriq in lung cancer
Roche’s Tecentriq may have fallen behind Merck’s Keytruda in the first-line non-small cell lung cancer population following releases at the annual meeting of the American Society of Clinical Oncology.
-
13 June 2018
Single-country studies dominate immuno-oncology trials, 2008-2017
GlobalData has reviewed the location of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017.
-
13 June 2018
Eli Lilly’s Olumiant: how will it far among JAK inhibitors?
On June 1, Eli Lilly’s Olumiant (baricitinib) 2mg tablets received FDA approval for adult patients with moderately to severely active rheumatoid arthritis (RA) following a complete response letter from the...
-
12 June 2018
Efficacy bar unclear for Celgene’s Phase III Abraxane/gemcitabine
Celgene is testing Abraxane, which is approved to treat metastatic pancreatic cancer, as an adjuvant therapy in a late-stage trial, and will need to show superior overall survival data compared...
-
12 June 2018
Unmet needs must be addressed to optimise AIS management
While the last two decades have brought important advances in our knowledge of stroke pathophysiology, awareness of symptoms, and improvements in acute stroke care, significant clinical and environmental unmet needs...
-
12 June 2018
ASCO 2018: Roche’s polatuzumab vedotin results show promise in DLBCL
Updated Phase II data for Roche’s polatuzumab vedotin in relapsed / refractory (R/R) follicular lymphoma (FL) and diffuse large b-cell lymphoma (DLBCL) patients were presented by Laurie Sehn, MD, during...
